Ikena Oncology

Site - Secondary

  • Contact
  • LinkedIn
  • Twitter

Site - Top

  • About
    • Our Company
    • Leadership
    • Partners
    • Contact
  • Focus
    • Our Approach
    • Publications
  • Pipeline
    • Development Pipeline
    • IK-930 TEAD Inhibitor
    • IK-007 EP4 Antagonist
    • IK-175 AHR Antagonist
    • IK-412 Kynase Program
  • Careers
    • Culture
    • Job Opportunities
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financial Filings
    • Corporate Governance
    • Investor Resources
  • Site - Top

    • About
      • Our Company
      • Leadership
      • Partners
      • Contact
    • Focus
      • Our Approach
      • Publications
    • Pipeline
      • Development Pipeline
      • IK-930 TEAD Inhibitor
      • IK-007 EP4 Antagonist
      • IK-175 AHR Antagonist
      • IK-412 Kynase Program
    • Careers
      • Culture
      • Job Opportunities
    • Investors & Media
      • Corporate Profile
      • Press Releases
      • Events & Presentations
      • Stock Information
      • Financial Filings
      • Corporate Governance
      • Investor Resources
    • Contact
    • Privacy Policy
    • Terms of Use
    • LinkedIn
    • Twitter

SEC Filings

Filing date Form Description View
Apr 05, 2021 SC 13G

A statement of beneficial ownership of common stock by certain persons

0000921895-21-000937.pdf
0000921895-21-000937.rtf
0000921895-21-000937.xls
View HTML
Apr 05, 2021 SC 13G

A statement of beneficial ownership of common stock by certain persons

0001140361-21-011655.pdf
0001140361-21-011655.rtf
0001140361-21-011655.xls
View HTML
Apr 09, 2021 SC 13G

A statement of beneficial ownership of common stock by certain persons

0001104659-21-048782.pdf
0001104659-21-048782.rtf
0001104659-21-048782.xls
View HTML
Apr 12, 2021 SC 13G

A statement of beneficial ownership of common stock by certain persons

0000315066-21-001500.pdf
0000315066-21-001500.rtf
View HTML
Mar 22, 2021 S-1/A

Amended Registration statement for face-amount certificate companies

0001193125-21-088609.pdf
0001193125-21-088609.rtf
0001193125-21-088609.xls
View HTML
Apr 13, 2021 4/A

Amendment to a previously filed 4

0000947871-21-000420.pdf
0000947871-21-000420.rtf
0000947871-21-000420.xls
View HTML
Apr 14, 2021 4/A

Amendment to a previously filed 4

0000947871-21-000426.pdf
0000947871-21-000426.rtf
0000947871-21-000426.xls
View HTML
Feb 11, 2021 DRS/A

Amendment to a previously filed DRS

0000950123-21-001690.pdf
0000950123-21-001690.rtf
0000950123-21-001690.xls
View HTML
Mar 30, 2021 3/A

An amendment to a 3 filing. Non-EDGAR filing

0000899243-21-013930.pdf
0000899243-21-013930.rtf
0000899243-21-013930.xls
View HTML
Jan 08, 2021 DRS

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

0000950123-21-000138.pdf
0000950123-21-000138.rtf
0000950123-21-000138.xls
View HTML

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Next page Next ›
  • Last page Last »

Data provided by Kaleidoscope.

Site - Side

  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
  • Financial Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
  • Investor Resources
    • Investor FAQs
    • Investor Email Alerts
    • Contact IR

Investors & Media Contact

  • Argot Partners
  • (212) 600-1902
  • ikena@argotpartners.com

Tools

  • Print Page
  • Email Alerts
  • RSS Feeds
Footer Logo
Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210
  • Privacy Policy
  • Terms of Use
Footer Logo
Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210
  • About
  • Our Company
  • Leadership
  • Partners
  • Contact
  • Focus
  • Our Approach
  • Publications
  • Pipeline
  • Development Pipeline
  • IK-930 TEAD Inhibitor
  • RAS Signaling Program
  • IK-007 EP4 Antagonist
  • IK-175 AHR Antagonist
  • IK-412 Kynase Program
  • Careers
  • Culture
  • Job Opportunities
  • Investors & Media
  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Information
  • Financials & Filings
  • Corporate Governance
  • Investor Resources
  • Privacy Policy
  • Terms of Use
  • LinkedIn
  • Twitter
© 2021 Ikena Oncology™